Abbott Laboratories is expected to report its earnings with a projected revenue of $11.06 billion and normalized EPS of $1.26. EPS on a GAAP basis is estimated at $0.99, with cash flow from operations at $2.63 billion. Core diagnostics has faced challenges due to decreased COVID testing, but growth is anticipated at mid-single digits. Management expresses optimism about the medical devices sector, despite competitive pressures from GLP-1 drugs, suggesting that fears regarding product impacts are exaggerated and procedural volumes remain strong.
Abbott Laboratories is set to report earnings with key figures including revenue of $11.06 billion and normalized EPS of $1.26, which investors will closely monitor.
Core Diagnostics growth struggling due to declines in COVID testing volumes; Abbott predicts mid-single digit growth in the segment, vital for share performance.
Management expresses confidence in medical devices amid threats from GLP-1 drugs, asserting that concerns over product impacts are overstated.
Collection
[
|
...
]